Valstar (valrubicin)

Common side effects of Valstar include:

• bladder irritation (symptoms such as pain, spasm, frequent urge to urinate, and
• blood in the urine),
• urinary incontinence,
• urinary tract infection, and
• nausea

Valstar usually will cause urine to turn a reddish color for about 24 hours following a dose. This is a normal, harmless side effect of Valstar and should not be mistaken for blood in the urine.

Recommended Dosing

For Intravesical Use Only. Do NOT administer by intravenous or intramuscular routes.

Valstar is recommended at a dose of 800 mg administered intravesically once a week for six weeks. Delay administration at least two weeks after transurethral resection and/or fulguration.

• Based on findings in animal studies and its mechanism of action, Valstar can cause fetal harm when administered to a pregnant females.
• There are no available data in pregnant females to inform the drug-associated risk.
• There are no data on the presence of valrubicin or its metabolites in human milk, the effects of valrubicin on the breastfed infant, or its effects on milk production.
• Because of the potential for serious adverse reactions in breast-fed infants from valrubicin, advise a lactating female not to breastfeed during treatment with Valstar and for 2 weeks after the final dose.